Genomic aberrations in chronic lymphocytic leukemia (CLL) are significant independent predictors of disease progression and survival. A study of 325 CLL patients identified chromosomal abnormalities in 82% of cases, with the most common being 13q deletion (55%), 11q deletion (18%), 12q trisomy (16%), 17p deletion (7%), and 6q deletion (6%). These abnormalities were categorized into five groups, with median survival times of 32, 79, 114, 111, and 133 months, respectively. Patients with 17p or 11q deletions had more advanced disease and shorter survival times. Multivariate analysis showed that 17p deletion, 11q deletion, age, Binet stage, serum lactate dehydrogenase level, and white-cell count were significant prognostic factors. The study highlights the importance of genomic aberrations in risk-adapted treatment strategies for CLL. The findings suggest that patients with 13q deletion as the sole abnormality have the best prognosis, while those with 17p deletion have the worst. These results have important implications for the clinical management of CLL, particularly in younger patients. The study used fluorescence in situ hybridization to detect chromosomal abnormalities, which is more sensitive than conventional cytogenetic analysis. The results indicate that molecular cytogenetic methods can detect genomic aberrations in over 80% of CLL patients, which is twice as frequent as chromosome banding. The study also found that patients with 17p deletion or p53 mutation have a poor prognosis, and that 11q deletions are associated with rapid disease progression and shorter survival times. The findings support the use of genomic aberrations as prognostic markers in CLL.Genomic aberrations in chronic lymphocytic leukemia (CLL) are significant independent predictors of disease progression and survival. A study of 325 CLL patients identified chromosomal abnormalities in 82% of cases, with the most common being 13q deletion (55%), 11q deletion (18%), 12q trisomy (16%), 17p deletion (7%), and 6q deletion (6%). These abnormalities were categorized into five groups, with median survival times of 32, 79, 114, 111, and 133 months, respectively. Patients with 17p or 11q deletions had more advanced disease and shorter survival times. Multivariate analysis showed that 17p deletion, 11q deletion, age, Binet stage, serum lactate dehydrogenase level, and white-cell count were significant prognostic factors. The study highlights the importance of genomic aberrations in risk-adapted treatment strategies for CLL. The findings suggest that patients with 13q deletion as the sole abnormality have the best prognosis, while those with 17p deletion have the worst. These results have important implications for the clinical management of CLL, particularly in younger patients. The study used fluorescence in situ hybridization to detect chromosomal abnormalities, which is more sensitive than conventional cytogenetic analysis. The results indicate that molecular cytogenetic methods can detect genomic aberrations in over 80% of CLL patients, which is twice as frequent as chromosome banding. The study also found that patients with 17p deletion or p53 mutation have a poor prognosis, and that 11q deletions are associated with rapid disease progression and shorter survival times. The findings support the use of genomic aberrations as prognostic markers in CLL.